At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
Propranololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant (HCT) Recipients
In Brief
A Phase 2 clinical trial evaluating Propranolol for Multiple Myeloma. Completed, enrolled 25 participants across 1 site.
Detailed Summary
This is a randomized controlled pilot study designed to evaluate whether the beta-adrenergic antagonist propranolol is effective in decreasing gene expression of stress-mediated beta-adrenergic pathways among a cohort of individuals receiving an autologous hematopoietic stem cell transplant (HCT) for multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsUniversity of California, Los Angeles
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2015
Enrollment StartJul 2015
Primary CompletionJul 2018
Study CompletionFeb 2020
TodayJul 2026
First PostedApr 17, 2015
Enrollment StartJul 17, 2015
Primary CompletionJul 1, 2018
Study CompletionFeb 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.2 years ago
Interventions
Propranololdrug